MOTS-C (10mg, 20mg, 30mg, 40mg)

MOTS-c (10mg / 40mg): Mitochondrial Open Reading Frame of the 12S rRNA Type c — The 16-Amino-Acid Mitochondrial-Derived Peptide That Activates AMPK, Improves Insulin Sensitivity, and Functions as an "Exercise Mimetic" by Targeting the Folate-Purine-AMPK Metabolic Axis

MOTS-c (pronounced "mots-see"), an acronym for "Mitochondrial Open Reading Frame of the Twelve S rRNA, type c," is a 16-amino-acid peptide encoded by a small open reading frame (sORF) within the mitochondrial 12S ribosomal RNA gene (MT-RNR1) — making it one of a growing class of "mitochondrial-derived peptides" (MDPs) that are encoded by the mitochondrial genome rather than the nuclear genome. Discovered in 2015 by a research team led by Dr. Pinchas Cohen and Dr. Changhan Lee at the University of Southern California (USC) Leonard Davis School of Gerontology, and published in the journal Cell Metabolism, MOTS-c was the first mitochondrial-derived peptide shown to act as a systemic hormone — circulating in the bloodstream and regulating metabolic homeostasis in distant tissues, rather than acting only locally within mitochondria. The key biological activity of MOTS-c is the activation of AMP-activated protein kinase (AMPK) — the cell's master energy sensor that is also activated by physical exercise, caloric restriction, and hypoxia — leading to increased glucose uptake, enhanced fatty acid oxidation, improved insulin sensitivity, and mitochondrial biogenesis. Uniquely, MOTS-c activates AMPK not by direct allosteric activation (as does AICAR, a direct AMPK activator) but through a specific metabolic mechanism involving inhibition of the folate-methionine cycle and de novo purine biosynthesis, leading to accumulation of the AMPK activator AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) within cells — this "folate-purine-AMPK axis" is the defining mechanistic feature that distinguishes MOTS-c from other AMPK activators. MOTS-c has gained significant attention as an "exercise mimetic" (a compound that reproduces some of the metabolic benefits of physical exercise without actual exercise), and was added to the World Anti-Doping Agency (WADA) Prohibited List in 2021 as a "hormone and metabolic modulator" — a testament to its potent metabolic effects. Preclinical studies in mice have shown that MOTS-c administration prevents weight gain and hepatic steatosis (fatty liver) on a high-fat diet, improves exercise endurance (running time on a treadmill), extends lifespan in some models, and improves insulin sensitivity — though human clinical data remain limited, with small Phase I/II studies showing safety and some metabolic signals but no large-scale efficacy trials to date.

AMPK Activators Comparison: MOTS-c vs. AICAR vs. Metformin vs. Exercise

As shown in the comparison table above, MOTS-c occupies a unique position among AMPK-activating interventions: it is a naturally occurring mitochondrial-derived peptide (not a synthetic drug or nucleotide analog), it acts as a systemic circulating hormone (not just a local tissue factor), and it activates AMPK through a unique and specific mechanism — the folate-purine-AMPK axis — that is distinct from both direct AMPK activators like AICAR and indirect AMPK activators like metformin (which works through mitochondrial complex I inhibition) and exercise (which works through muscle contraction-induced AMP/ATP ratio changes and Ca²⁺/CaMKKβ signaling). While MOTS-c shares many of the metabolic downstream effects of other AMPK activators (increased glucose uptake, enhanced fatty acid oxidation, improved insulin sensitivity, mitochondrial biogenesis), its unique mechanism of action — involving inhibition of the folate-methionine cycle and de novo purine biosynthesis — may confer distinct metabolic effects and tissue targeting that are not fully shared by other AMPK activators. The WADA prohibition of MOTS-c (along with AICAR) as an "exercise mimetic" further underscores its potent metabolic and performance-enhancing potential, though it is important to note that human clinical data for MOTS-c remain limited compared to the extensive clinical experience with metformin and the well-established benefits of exercise itself.

Mechanism of Action: The Folate-Purine-AMPK Axis

The mechanism of action of MOTS-c is one of its most distinctive and well-characterized features. Unlike many metabolic peptides that act through cell surface G protein-coupled receptors, MOTS-c appears to act intracellularly — it is taken up by cells (particularly skeletal muscle cells, hepatocytes, and adipocytes) and exerts its effects through modulation of intracellular metabolic pathways. The key steps are:

1. Cellular uptake and mitochondrial localization — MOTS-c, as a small 16-amino-acid peptide, is taken up by target cells (skeletal muscle, liver, adipose) through mechanisms that are not yet fully elucidated but may involve peptide transporters or endocytosis. Once inside the cell, MOTS-c localizes to both the cytoplasm and mitochondria (consistent with its mitochondrial origin), where it interacts with metabolic enzymes involved in one-carbon metabolism and purine biosynthesis.
2. Inhibition of the folate-methionine cycle — The primary intracellular target of MOTS-c is the folate-methionine cycle (also called one-carbon metabolism), a critical metabolic pathway that involves the transfer of one-carbon units for nucleotide synthesis, amino acid metabolism, and epigenetic methylation. MOTS-c inhibits a key enzyme in this pathway — specifically, it has been shown to interact with and inhibit the activity of enzymes involved in folate-dependent one-carbon metabolism, leading to disruption of the folate cycle and accumulation of intermediate metabolites. This inhibition of the folate-methionine cycle is the upstream event that triggers the downstream AMPK activation cascade.
3. Disruption of de novo purine biosynthesis and AICAR accumulation — The folate-methionine cycle is closely linked to de novo purine biosynthesis (the pathway by which cells synthesize purine nucleotides [ATP, GTP] from scratch). Inhibition of the folate cycle by MOTS-c disrupts purine biosynthesis, leading to the accumulation of a key intermediate metabolite: AICAR (5-aminoimidazole-4-carboxamide ribonucleotide, also called ZMP). AICAR is a well-known direct activator of AMPK — it is converted intracellularly to ZMP, which mimics the structure of AMP and allosterically activates AMPK by binding to the AMP-binding regulatory sites on the AMPK γ-subunit. Thus, MOTS-c indirectly activates AMPK by causing intracellular accumulation of AICAR/ZMP — this is the "folate-purine-AMPK axis" that is the defining mechanistic feature of MOTS-c.
4. AMPK activation — The accumulated AICAR/ZMP binds to the γ-subunit of AMPK, causing allosteric activation and promoting phosphorylation of the AMPK α-subunit at Thr172 (the activation loop) by upstream kinases such as LKB1 (liver kinase B1) and CaMKKβ (Ca²⁺/calmodulin-dependent protein kinase kinase β). Activated AMPK then phosphorylates a wide range of downstream target proteins, orchestrating a metabolic shift from energy-consuming (anabolic) processes to energy-producing (catabolic) processes.
5. Downstream metabolic effects of AMPK activation — Activated AMPK produces the following key metabolic effects: (a) Increased glucose uptake — AMPK phosphorylates and activates AS160 (TBC1D4), which promotes translocation of GLUT4 glucose transporters to the cell membrane, increasing glucose uptake into skeletal muscle and adipose tissue (independent of insulin, via the AMPK pathway rather than the PI3K/Akt insulin signaling pathway); (b) Enhanced fatty acid oxidation — AMPK phosphorylates and inactivates acetyl-CoA carboxylase (ACC), reducing malonyl-CoA levels (which is an inhibitor of carnitine palmitoyltransferase 1 [CPT1], the rate-limiting enzyme for fatty acid entry into mitochondria), thereby increasing fatty acid oxidation and reducing lipid accumulation; (c) Mitochondrial biogenesis — AMPK phosphorylates and activates PGC-1α (peroxisome proliferator-activated receptor γ coactivator 1α), the master regulator of mitochondrial biogenesis, leading to increased mitochondrial content and oxidative capacity in skeletal muscle; (d) Suppression of hepatic gluconeogenesis — AMPK inhibits the expression of gluconeogenic genes (PEPCK, glucose-6-phosphatase) in the liver, reducing hepatic glucose output; (e) Improved insulin sensitivity — The combination of increased glucose uptake, enhanced fatty acid oxidation, reduced lipid accumulation (particularly ectopic lipid in muscle and liver, which causes insulin resistance), and suppression of hepatic gluconeogenesis collectively improves whole-body insulin sensitivity — this is the basis for MOTS-c's potential as an insulin-sensitizing and anti-diabetic agent.
6. Nuclear translocation and gene regulation (stress response) — In addition to its cytoplasmic metabolic effects, MOTS-c has been shown to translocate to the nucleus in response to metabolic stress (e.g., glucose deprivation, exercise), where it regulates the expression of genes involved in stress resistance and metabolic homeostasis. This nuclear translocation is AMPK-dependent — activated AMPK promotes MOTS-c nuclear import, where it may interact with transcription factors and chromatin regulators to modulate gene expression. This dual cytoplasmic-nuclear activity distinguishes MOTS-c from many other metabolic peptides and may contribute to its long-term adaptive effects (e.g., improved stress resistance, longevity in preclinical models).

"MOTS-c represents a paradigm shift in our understanding of mitochondrial function — the mitochondrial genome is not merely a relic of endosymbiosis encoding a handful of respiratory chain proteins, but a rich source of bioactive peptides that act as systemic hormones regulating metabolic homeostasis. The discovery that a 16-amino-acid peptide encoded within the 12S rRNA gene can circulate in the blood, activate AMPK in skeletal muscle, and improve insulin sensitivity challenges the traditional view of mitochondria as purely energy-producing organelles and opens new avenues for metabolic disease therapy."
— Adapted from Lee et al., Cell Metabolism, 2015 (original MOTS-c discovery paper)^[1]; reviewed in PMC9570330, 2022^[2]

Preclinical Evidence, Human Studies, and the "Exercise Mimetic" Concept

The preclinical evidence for MOTS-c is robust and comes primarily from studies conducted in mouse models by the Cohen laboratory at USC and other research groups. Key findings include:

• High-fat diet (HFD) studies — In the original 2015 Cell Metabolism paper^[1], Lee et al. demonstrated that daily MOTS-c administration to mice fed a high-fat diet prevented weight gain (compared to vehicle-treated HFD controls that gained significant weight), prevented hepatic steatosis (fatty liver accumulation), and improved glucose tolerance and insulin sensitivity. These effects were attributed to AMPK activation in skeletal muscle and liver, leading to increased fatty acid oxidation and reduced lipid accumulation.
• Exercise endurance — MOTS-c administration has been shown to increase exercise endurance in mice, as measured by running time to exhaustion on a treadmill. This effect is consistent with AMPK activation and increased mitochondrial biogenesis (PGC-1α) in skeletal muscle, which improves oxidative capacity and fatigue resistance — supporting the "exercise mimetic" concept^[3].
• Lifespan and healthspan — Some preclinical studies have suggested that MOTS-c administration may extend lifespan and improve healthspan (the period of life free from age-related disease and disability) in mice, particularly in the context of metabolic stress or high-fat feeding. These effects are thought to be mediated by AMPK activation, improved metabolic homeostasis, reduced oxidative stress, and enhanced stress resistance — though these findings require further validation and have not yet been demonstrated in humans^[2][4].
• Age-related decline — Circulating MOTS-c levels have been shown to decline with age in humans, consistent with the general decline in mitochondrial function that occurs with aging (mitochondrial dysfunction is a hallmark of aging). This age-related decline in MOTS-c may contribute to the metabolic deterioration (insulin resistance, reduced muscle mass, increased adiposity) that occurs with aging, and has motivated interest in MOTS-c as a potential "anti-aging" or "geroprotective" intervention^[2][5].
• Human clinical studies — Human clinical data for MOTS-c remain limited. Small Phase I/II studies have been conducted primarily to assess safety, tolerability, and pharmacokinetics, with some preliminary metabolic signals (e.g., trends toward improved insulin sensitivity, changes in circulating metabolites consistent with folate cycle inhibition). However, no large-scale, randomized, placebo-controlled clinical trials have yet demonstrated definitive clinical efficacy for MOTS-c in any indication (e.g., type 2 diabetes, obesity, metabolic syndrome). The limited human data, combined with the robust preclinical evidence, represent both the promise and the current limitation of MOTS-c as a therapeutic agent^[2][4].
• WADA prohibition — In 2021, the World Anti-Doping Agency (WADA) added MOTS-c to its Prohibited List under the category of "Hormone and Metabolic Modulators" (S4.4), alongside AICAR and other exercise mimetics. This prohibition reflects WADA's assessment that MOTS-c has the potential to enhance athletic performance (through improved endurance, increased fatty acid oxidation, and improved metabolic efficiency) and that it is not a legitimate medical therapy at this time. The WADA listing has also had the effect of increasing public awareness of MOTS-c and its potential as a performance-enhancing substance^[6].

Safety, Side Effects, and Important Considerations

MOTS-c is generally considered to have a favorable safety profile in preclinical studies, with no significant toxicity observed at therapeutic doses in animal models. However, because human clinical data are limited, the long-term safety profile of MOTS-c in humans is not fully established. Potential side effects and considerations include: injection site reactions (pain, redness, swelling, itching — common with subcutaneous peptide injections), mild hypoglycemia (theoretical, due to increased glucose uptake and improved insulin sensitivity — particularly when combined with insulin or oral hypoglycemic agents), gastrointestinal disturbances (nausea, diarrhea — reported in some users, possibly due to effects on gastrointestinal motility or folate cycle inhibition in the gut), headache, fatigue, and flushing. Less common but important considerations include: (1) Folate cycle inhibition and one-carbon metabolism — Because MOTS-c inhibits the folate-methionine cycle, long-term or high-dose use could theoretically interfere with one-carbon metabolism, which is critical for nucleotide synthesis, amino acid metabolism, and epigenetic methylation (DNA and histone methylation). This could have implications for cell proliferation, gene expression, and fetal development — MOTS-c should be avoided in pregnancy and lactation due to potential effects on fetal development and one-carbon metabolism; (2) Interaction with folate antagonists and methotrexate — Because MOTS-c inhibits the folate cycle, it could theoretically interact with other folate-antagonist drugs (e.g., methotrexate, trimethoprim, pyrimethamine), potentially enhancing or altering their effects. Patients taking these medications should exercise caution; (3) Hypoglycemia risk with antidiabetic medications — MOTS-c improves insulin sensitivity and increases glucose uptake, which could increase the risk of hypoglycemia (low blood sugar) when combined with insulin, sulfonylureas, or other hypoglycemic agents. Blood glucose should be monitored closely in diabetic patients using MOTS-c; (4) Theoretical cancer risk — AMPK activation is generally considered to have anti-cancer effects (AMPK is a tumor suppressor that inhibits mTOR, a key driver of cell proliferation), and MOTS-c has shown some anti-tumor effects in preclinical models. However, because MOTS-c also promotes cell proliferation and mitochondrial biogenesis in some contexts, the long-term effects on cancer risk are not fully established and require further study; (5) Limited human data — Perhaps the most important consideration is that MOTS-c is a research chemical with limited human clinical data. The optimal dose, dosing frequency, long-term safety, and clinical efficacy in humans have not been definitively established. Products sold online as "MOTS-c" may have variable purity, potency, and quality, and may contain contaminants or incorrect dosages; (6) WADA prohibited status — MOTS-c is prohibited by WADA for use by competitive athletes. Athletes subject to anti-doping testing should be aware that MOTS-c use could result in a positive doping test and disciplinary action. Contraindications include: pregnancy and lactation (due to potential effects on fetal development and one-carbon metabolism), active cancer (theoretical, until further data), hypersensitivity to MOTS-c or any excipients, and use by competitive athletes subject to WADA regulations. MOTS-c is for in-vitro laboratory research use only and is not for human or veterinary use.

References

1. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. doi:10.1016/j.cmet.2015.02.004. (Original MOTS-c discovery paper, USC, Cohen lab)
2. Kim KH, Son GH, Lee C, et al. MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases. Int J Mol Sci. 2022;23(19):11285. doi:10.3390/ijms231911285. (PMC9570330, comprehensive review of MOTS-c in aging)
3. Reynolds TH, Kumar V, Dey R, et al. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Pharmacol Res. 2023;187:106580. doi:10.1016/j.phrs.2022.106580. (PMC9905433, therapeutic potential review)
4. Zeng J, Miller BJ, Andrew AY, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Sci Rep. 2021;11(1):1740. doi:10.1038/s41598-020-79357-3. (Exercise-induced MOTS-c, age-related physical decline)
5. Dincer F, Sevgili E, Kilic U, et al. Mitochondrial derived peptides (humanin, MOTS-c, and SHLP1-6) in aging and age-related diseases: a systematic review. Exp Gerontol. 2022;167:111908. doi:10.1016/j.exger.2022.111908. (Age-related decline in MDPs, systematic review)
6. World Anti-Doping Agency (WADA). The 2024 Prohibited List — International Standard. WADA. 2024. (MOTS-c listed under S4.4 Hormone and Metabolic Modulators, prohibited since 2021)
7. Cohen P, Keller JN, Dyches D, et al. The emerging role of mitochondrial-derived peptides in aging and disease. Trends Endocrinol Metab. 2020;31(1):70-82. doi:10.1016/j.tem.2019.09.002. (MDP review, Cohen lab, USC)
8. Fuku N, Guo L, Tran DD, et al. Mitochondrial-derived peptide MOTS-c and its potential role in metabolic regulation. Peptides. 2015;72:140-145. doi:10.1016/j.peptides.2015.07.007. (MOTS-c metabolic regulation, early study)